Cargando…

Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood

Adolescent and young adult (AYA) patients with hematological malignancy aged 15 to 39 years are recognized as a separate entity, and the efficacy and safety of unrelated cord blood transplantation (CBT) for chronic myeloid leukemia (CML) in AYA patients has not been reported. From March 2002 to June...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Changcheng, Zhu, Xiaoyu, Tang, Baolin, Zhang, Xuhan, Zhang, Lei, Geng, Liangquan, Liu, Huilan, Sun, Zimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788685/
https://www.ncbi.nlm.nih.gov/pubmed/29416817
http://dx.doi.org/10.18632/oncotarget.22979
_version_ 1783296124263596032
author Zheng, Changcheng
Zhu, Xiaoyu
Tang, Baolin
Zhang, Xuhan
Zhang, Lei
Geng, Liangquan
Liu, Huilan
Sun, Zimin
author_facet Zheng, Changcheng
Zhu, Xiaoyu
Tang, Baolin
Zhang, Xuhan
Zhang, Lei
Geng, Liangquan
Liu, Huilan
Sun, Zimin
author_sort Zheng, Changcheng
collection PubMed
description Adolescent and young adult (AYA) patients with hematological malignancy aged 15 to 39 years are recognized as a separate entity, and the efficacy and safety of unrelated cord blood transplantation (CBT) for chronic myeloid leukemia (CML) in AYA patients has not been reported. From March 2002 to June 2015, total of 106 CML patients received allogeneic hematopoietic cell transplantation (allo-HCT) in our center. Included in the present study were CML patients aged 15 to 39 years who received unrelated CBT or sibling allo-HCT, and 74 consecutive AYA patients with CML enrolled in this analysis. The day-100 cumulative incidences of grade 2–4 aGVHD and grade 3–4 aGVHD were similar following CBT and sibling-PBSCT/BMT. The cumulative incidences of cGVHD and extensive cGVHD were 21.7% and 5.3% in the CBT cohort, which were significantly lower than those in the sibling-PBSCT/BMT cohort (58.0% and 45.5%), respectively (p = 0.046, 0.008). There was no significant difference between the two cohorts in terms of transplant-related mortality (TRM), relapse, and long-term survival (overall survival and leukemia-free survival). The 5-year probability of GVHD-free/relapse-free survival (GRFS) was 47.9% and 33.4% in the CBT and the sibling-PBSCT/BMT cohorts, respectively (p = 0.632); among patients who survived more than 100 days after transplantation (n = 61), the 5-year probability of chronic GVHD-free, relapse-free survival (CRFS) was 66.2% in the CBT cohort, which was significantly higher than that in the sibling-PBSCT/BMT cohort (37.4%) (p = 0.037). Our study suggests that for AYA patients with CML, transplantation using unrelated CB offers comparable outcomes to sibling -PBSCT/BMT, including similar aGVHD, TRM, relapse, and long-term survival; however, from the perspective of quality of life, unrelated CBT have a lower incidence of cGVHD and a higher CRFS among survivors.
format Online
Article
Text
id pubmed-5788685
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57886852018-02-07 Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood Zheng, Changcheng Zhu, Xiaoyu Tang, Baolin Zhang, Xuhan Zhang, Lei Geng, Liangquan Liu, Huilan Sun, Zimin Oncotarget Clinical Research Paper Adolescent and young adult (AYA) patients with hematological malignancy aged 15 to 39 years are recognized as a separate entity, and the efficacy and safety of unrelated cord blood transplantation (CBT) for chronic myeloid leukemia (CML) in AYA patients has not been reported. From March 2002 to June 2015, total of 106 CML patients received allogeneic hematopoietic cell transplantation (allo-HCT) in our center. Included in the present study were CML patients aged 15 to 39 years who received unrelated CBT or sibling allo-HCT, and 74 consecutive AYA patients with CML enrolled in this analysis. The day-100 cumulative incidences of grade 2–4 aGVHD and grade 3–4 aGVHD were similar following CBT and sibling-PBSCT/BMT. The cumulative incidences of cGVHD and extensive cGVHD were 21.7% and 5.3% in the CBT cohort, which were significantly lower than those in the sibling-PBSCT/BMT cohort (58.0% and 45.5%), respectively (p = 0.046, 0.008). There was no significant difference between the two cohorts in terms of transplant-related mortality (TRM), relapse, and long-term survival (overall survival and leukemia-free survival). The 5-year probability of GVHD-free/relapse-free survival (GRFS) was 47.9% and 33.4% in the CBT and the sibling-PBSCT/BMT cohorts, respectively (p = 0.632); among patients who survived more than 100 days after transplantation (n = 61), the 5-year probability of chronic GVHD-free, relapse-free survival (CRFS) was 66.2% in the CBT cohort, which was significantly higher than that in the sibling-PBSCT/BMT cohort (37.4%) (p = 0.037). Our study suggests that for AYA patients with CML, transplantation using unrelated CB offers comparable outcomes to sibling -PBSCT/BMT, including similar aGVHD, TRM, relapse, and long-term survival; however, from the perspective of quality of life, unrelated CBT have a lower incidence of cGVHD and a higher CRFS among survivors. Impact Journals LLC 2017-12-05 /pmc/articles/PMC5788685/ /pubmed/29416817 http://dx.doi.org/10.18632/oncotarget.22979 Text en Copyright: © 2018 Zheng et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Zheng, Changcheng
Zhu, Xiaoyu
Tang, Baolin
Zhang, Xuhan
Zhang, Lei
Geng, Liangquan
Liu, Huilan
Sun, Zimin
Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
title Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
title_full Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
title_fullStr Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
title_full_unstemmed Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
title_short Transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic GVHD-free and relapse-free survival among survivors with cord blood
title_sort transplants of unrelated cord blood or sibling allogeneic peripheral blood stem cells/bone marrow in adolescent and young adults with chronic myeloid leukemia: comparable outcomes but better chronic gvhd-free and relapse-free survival among survivors with cord blood
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788685/
https://www.ncbi.nlm.nih.gov/pubmed/29416817
http://dx.doi.org/10.18632/oncotarget.22979
work_keys_str_mv AT zhengchangcheng transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood
AT zhuxiaoyu transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood
AT tangbaolin transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood
AT zhangxuhan transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood
AT zhanglei transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood
AT gengliangquan transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood
AT liuhuilan transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood
AT sunzimin transplantsofunrelatedcordbloodorsiblingallogeneicperipheralbloodstemcellsbonemarrowinadolescentandyoungadultswithchronicmyeloidleukemiacomparableoutcomesbutbetterchronicgvhdfreeandrelapsefreesurvivalamongsurvivorswithcordblood